C1q-Targeted miR-33 ASO Delivery for APOE4 Hyper-Lipidation via Microglial Receptor-Mediated Transcytosis

This hypothesis proposes using C1q protein as a brain-penetrant delivery vehicle for miR-33 antisense oligonucleotides (ASOs) to achieve therapeutic hyper-lipidation of APOE4 particles in Alzheimer's disease. The strategy exploits C1q's natural ability to cross the blood-brain barrier through receptor-mediated transcytosis at brain endothelial cells, which express complement receptors including C1qR and gC1qR. By conjugating miR-33 ASOs to C1q, the therapeutic payload would be selectively delivered to brain microglia, which are the primary CNS source of APOE and express high levels of complement receptors. Upon uptake by microglia via C1q receptor binding, the ASOs would inhibit miR-33a/33b, leading to dramatic upregulation of ABCA1 expression and cholesterol efflux capacity.

This hypothesis proposes using C1q protein as a brain-penetrant delivery vehicle for miR-33 antisense oligonucleotides (ASOs) to achieve therapeutic hyper-lipidation of APOE4 particles in Alzheimer's disease. The strategy exploits C1q's natural ability to cross the blood-brain barrier through receptor-mediated transcytosis at brain endothelial cells, which express complement receptors including C1qR and gC1qR. By conjugating miR-33 ASOs to C1q, the therapeutic payload would be selectively delivered to brain microglia, which are the primary CNS source of APOE and express high levels of complement receptors. Upon uptake by microglia via C1q receptor binding, the ASOs would inhibit miR-33a/33b, leading to dramatic upregulation of ABCA1 expression and cholesterol efflux capacity. This would force the structurally-impaired APOE4 protein into a compensatory hyper-lipidated state, potentially overcoming its inherent domain interaction limitations and Arg112/Arg158-mediated lipidation defects. The hyper-lipidated APOE4 particles would exhibit enhanced amyloid-beta clearance capacity, mimicking the superior clearance properties of APOE2/3 isoforms. This approach addresses the two critical bottlenecks in APOE4-targeted therapeutics: poor brain penetration of nucleic acid therapeutics and the need for cell-type specific delivery to avoid systemic metabolic disruption. The C1q conjugation provides both blood-brain barrier penetration and microglial targeting specificity, while the miR-33 inhibition mechanism directly addresses the fundamental lipidation deficiency underlying APOE4-mediated neurodegeneration.